Data_Sheet_1_Statins and Histone Deacetylase Inhibitors Affect Lamin A/C – Histone Deacetylase 2 Interaction in Human Cells.pdf
We recently identified lamin A/C as a docking molecule for human histone deacetylase 2 (HDAC2) and showed involvement of HDAC2-lamin A/C complexes in the DNA damage response. We further showed that lamin A/C-HDAC2 interaction is altered in Hutchinson-Gilford Progeria syndrome and other progeroid laminopathies. Here, we show that both inhibitors of lamin A maturation and small molecules inhibiting HDAC activity affect lamin A/C interaction with HDAC2. While statins, which inhibit prelamin A processing, reduce protein interaction, HDAC inhibitors strengthen protein binding. Moreover, treatment with HDAC inhibitors restored the enfeebled lamin A/C-HDAC2 interaction observed in HGPS cells. Based on these results, we propose that prelamin A levels as well as HDAC2 activation status might influence the extent of HDAC2 recruitment to the lamin A/C-containing platform and contribute to modulate HDAC2 activity. Our study links prelamin A processing to HDAC2 regulation and provides new insights into the effect of statins and histone deacetylase inhibitors on lamin A/C functionality in normal and progeroid cells.
History
References
- https://doi.org//10.1371/currents.md.f1e2379fa632f8135577333dd92ca83b
- https://doi.org//10.1007/s10522-018-9758-4
- https://doi.org//10.1007/s00418-012-0977-5
- https://doi.org//10.4081/ejh.2011.e36
- https://doi.org//10.1038/nature08085
- https://doi.org//10.1007/s00018-014-1727-8
- https://doi.org//10.1111/bcp.12928
- https://doi.org//10.18632/oncotarget.19363
- https://doi.org//10.1016/j.celrep.2015.10.006
- https://doi.org//10.4161/cc.24061
- https://doi.org//10.1001/jama.2018.3264
- https://doi.org//10.1155/2017/9175806
- https://doi.org//10.1080/19491034.2018.1460045
- https://doi.org//10.1002/jcb.21467
- https://doi.org//10.1242/jcs.133983
- https://doi.org//10.1111/acel.12824
- https://doi.org//10.1038/nsmb.1899
- https://doi.org//10.1016/j.bbrc.2008.10.079
- https://doi.org//10.4155/fmc-2016-0073
- https://doi.org//10.18632/oncotarget.4939
- https://doi.org//10.2217/epi.14.69
- https://doi.org//10.1101/cshperspect.a018713
- https://doi.org//10.1038/nm1786